Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma.
暂无分享,去创建一个
A. Hauschild | D. Schadendorf | R. Dummer | A. Ribas | C. Blank | I. Puzanov | J. Schachter | A. Daud | C. Robert | S. O’Day | Wei Zhou | C. Loquai | O. Hamid | A. Salama | S. Ebbinghaus | S. Kang | L. Cranmer | A. V. D. van den Eertwegh | J. Mehnert | D. Hille | S. Kang | S. Kang | S. Kang | S. Kang | S. Kang | S. O'Day
[1] A. Hauschild,et al. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial. , 2015, The Lancet. Oncology.
[2] Wei Zhou,et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. , 2015, The Lancet. Oncology.
[3] Dirk Schadendorf,et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. , 2015, The New England journal of medicine.
[4] J. Larkin,et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. , 2015, The New England journal of medicine.
[5] A. Ribas,et al. Anti-PD-1 therapy in melanoma. , 2015, Seminars in oncology.
[6] D. Schadendorf,et al. Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma. , 2015, European journal of cancer.
[7] C. Drake,et al. Immune checkpoint blockade: a common denominator approach to cancer therapy. , 2015, Cancer cell.
[8] G. Linette,et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. , 2015, The Lancet. Oncology.
[9] D. Schadendorf,et al. Nivolumab in previously untreated melanoma without BRAF mutation. , 2015, The New England journal of medicine.
[10] D. Schadendorf,et al. Functional and symptom impact of trametinib versus chemotherapy in BRAF V600E advanced or metastatic melanoma: quality-of-life analyses of the METRIC study. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[11] D. Osoba,et al. A global analysis of multitrial data investigating quality of life and symptoms as prognostic factors for survival in different tumor sites , 2014, Cancer.
[12] M. Atkins,et al. PD-1 as a potential target in cancer therapy , 2013, Cancer medicine.
[13] Antoni Ribas,et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. , 2013, The New England journal of medicine.
[14] Ali Montazeri,et al. Health and Quality of Life Outcomes , 2009 .
[15] J. Allison,et al. Checkpoint blockade in cancer immunotherapy. , 2007, Advances in immunology.
[16] M. Middleton,et al. Health-Related Quality of Life in Patients with Advanced Metastatic Melanoma: Results of a Randomized Phase III Study Comparing Temozolomide with Dacarbazine , 2003, Cancer investigation.
[17] G. Freeman,et al. PD‐1:PD‐L inhibitory pathway affects both CD4+ and CD8+ T cells and is overcome by IL‐2 , 2002, European journal of immunology.
[18] G. Freeman,et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation , 2001, Nature Immunology.
[19] G. Freeman,et al. Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation , 2000, The Journal of experimental medicine.
[20] J. Cormier,et al. Assessment of patient-reported outcomes in patients with melanoma. , 2011, Surgical oncology clinics of North America.
[21] D. Osoba,et al. Interpreting the significance of changes in health-related quality-of-life scores. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.